On December 17, 1999 the Rule Breaker Portfolio bought 630 shares of bioinformatics company Celera Genomics (NYSE: CRA). The cost was $79.50 per share plus an $8.00 commission. For the full rationale behind this Rule Breaking purchase, please see the buy report.
ACTION # STOCK PRICE COMS'N TOTAL COST BOUGHT 630 CRA $79.50 $8 $50,093.00Sell Stats
On April 24, 2002, the Rule Breaker Portfolio sold all 1260 of its shares (after a 2:1 stock split) in Celera Genomics, filled as 100 at $16.64 a share and 1160 at $16.30 a share, plus an $8 commission. We lost 59% of our investment in Celera Genomics, compared to a 23% loss in the S&P 500. For the rationale behind the sale, please see the sell report.
ACTION # STOCK PRICE COMS'N PROCEEDS SOLD 100 CRA $16.64 SOLD 1160 CRA $16.30 $8 $20,564.00
More from The Motley Fool
Solar Companies Are Set Up for a Strong Earnings Season
Rising demand and prices for solar panel prices bode well for manufacturers.
Today's Workers Aren't Optimistic About Raises and Promotions, Data Shows
Surprisingly, a large number of workers across the globe think their chances of a pay or title boost are pretty low. Here's how to bust out of that cycle and propel your career forward.
Could These High-Flying Tech Stocks Start Paying a Dividend?
Alphabet, Facebook, and Adobe don't do it yet, but that could change sooner than you think.